NCT03073733View on ClinicalTrials.gov

Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa

PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

November 13, 2020

Study Completion Date

November 13, 2020

Conditions
Retinitis Pigmentosa
Interventions
BIOLOGICAL

human retinal progenitor cells

live suspension of 3.0 or 6.0 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia

OTHER

Mock injection

pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection

Trial Locations (3)

90074

Retina-Vitreous Associates Medical Group, Los Angeles

92697

Gavin Herbert Eye Inst, Univ Cal Irvine, Irvine

02114

Ophthalmic Consultants of Boston, Boston

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

jCyte, Inc

INDUSTRY

NCT03073733 - Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa | Biotech Hunter | Biotech Hunter